Ceralasertib
As of the edition of 20 October 2026, Ceralasertib is a small molecule: stopped in 2025; acts on ATR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2025
- Kind
- Small molecule
- Registered trials
- 46, 5 stopped early
- Disease areas
- Cancer; Lungs and airways; Skin and connective tissue; Urinary and reproductive; Pregnancy and women's health; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Ceralasertib.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ATR | Serine/threonine-protein kinase ATR | Q13535 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 15 | 5 | 6 | 2 |
| Phase 2 | 29 | 5 | 16 | 3 |
| Phase 3 | 2 | 0 | 2 | 0 |
| All trials | 46 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| AstraZeneca | Lead sponsor of trials | 2013 to now |
| Acerta Pharma | Lead sponsor of trials | 2018 to now |